Edition:
United States

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

66.85USD
22 Jun 2018
Change (% chg)

$0.24 (+0.36%)
Prev Close
$66.61
Open
$66.25
Day's High
$67.25
Day's Low
$66.25
Volume
433,423
Avg. Vol
339,897
52-wk High
$69.68
52-wk Low
$45.31

Chart for

About

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $10,577.30
Shares Outstanding(Mil.): 158.22
Dividend: --
Yield (%): --

Financials

  SGEN.OQ Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -0.41 -- --
ROI: -6.37 -5.33 13.09
ROE: -6.63 -6.88 15.10

BRIEF-Seattle Genetics Reports Q1 Loss Per Share Of $0.73

* SEATTLE GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Apr 26 2018

Biotech group Genmab aims to own bigger share of new drug pipeline

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

Apr 10 2018

BRIEF-Seattle Genetics Says CEO Clay Siegall's 2017 Total Compensation Was $8.6 Mln Vs $9.6 Mln In 2016‍​

* SEATTLE GENETICS INC SAYS CEO CLAY B. SIEGALL'S 2017 TOTAL COMPENSATION WAS $8.6 MLN VS $9.6 MLN IN 2016 – SEC FILING‍​‍​ Source text: (https://bit.ly/2GxkWMO) Further company coverage:

Apr 04 2018

BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin

* SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Mar 26 2018

Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval

U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, making it the first new treatment in over 40 years.

Mar 20 2018

UPDATE 2-Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval

* Company expects $1 billion in Adcetris sales within few years

Mar 20 2018

BRIEF-Seattle Genetics Announces FDA Approval Of Adcetris

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) IN COMBINATION WITH CHEMOTHERAPY FOR ADULTS WITH PREVIOUSLY UNTREATED STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA

Mar 20 2018

Seattle Genetics' Hodgkin's lymphoma drug gets U.S. approval

U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients.

Mar 20 2018

BRIEF-Unum Therapeutics Sees IPO Of 5.8 Mln Shares Priced $12 - $14 Per Share

* UNUM THERAPEUTICS INC SEES IPO OF 5.8 MILLION SHARES OF COMMON STOCK PRICED TO BE BETWEEN $12.00 AND $14.00 PER SHARE - SEC FILING

Mar 19 2018

BRIEF-Seattle Genetics Appoints Alpna Seth To Board

* SEATTLE GENETICS APPOINTS DR. ALPNA SETH TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Mar 15 2018

Competitors

Earnings vs. Estimates